Securities code: 002370 securities abbreviation: Zhejiang Yatai Pharmaceutical Co.Ltd(002370) Announcement No.: 2022-004 bond Code: 128062 bond abbreviation: Asian medicine convertible bond
Zhejiang Yatai Pharmaceutical Co.Ltd(002370)
Announcement on abnormal fluctuation of stock trading
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Abnormal fluctuations in stock trading
Zhejiang Yatai Pharmaceutical Co.Ltd(002370) (hereinafter referred to as ” Zhejiang Yatai Pharmaceutical Co.Ltd(002370) ” or “the company”) shares (Securities abbreviation: Zhejiang Yatai Pharmaceutical Co.Ltd(002370) , securities code: 002370) deviated from the closing price for two consecutive trading days on January 10, 2022 and January 11, 2022 by more than 20%. According to the relevant regulations of Shenzhen Stock Exchange, it belongs to abnormal fluctuation of stock trading.
2、 Description of the company’s concern and verification
In view of the abnormal fluctuation of the company’s shares, the board of directors of the company has verified the relevant matters, and the relevant information is described as follows:
1. There is no need to correct or supplement the information disclosed by the company in the early stage.
2. The company has not found any unpublished material information that may or has had a great impact on the company’s stock trading price reported by the public media recently.
3. The disclosed business conditions and internal and external business environment of the company have not changed significantly. 4. The company has no major matters that should be disclosed but not disclosed about the company.
5. The former controlling shareholders of the company, Zhejiang Asia Pacific Group Co., Ltd. and its subsidiaries Shaoxing Keqiao Asia Pacific Real Estate Co., Ltd., Chen Yaogen and Zhong Wanzhen, were auctioned and sold off 182404110 shares of Zhejiang Yatai Pharmaceutical Co.Ltd(002370) shares, accounting for 33.99% of the total shares of the company, due to disputes over financial loan contracts with a number of banks and involving a number of litigation cases. The company’s largest shareholder Ningbo Fubang Jingye Group Co.Ltd(600768) Holding Group Co., Ltd. and its wholly-owned subsidiary Shanghai Hangui Investment Management Co., Ltd. obtained 57675566 Zhejiang Yatai Pharmaceutical Co.Ltd(002370) shares through judicial auction and secondary market purchase, accounting for 10.75% of the total share capital of Zhejiang Yatai Pharmaceutical Co.Ltd(002370) . At present, the ownership structure of the company is relatively scattered, and the shareholding ratio of the first two major shareholders is relatively close. The company is in the state of no controlling shareholder and no actual controller. 6. On January 11, 2022, the company received the agreement transfer notice from Bank Of Ningbo Co.Ltd(002142) Shaoxing Branch (hereinafter referred to as ” Bank Of Ningbo Co.Ltd(002142) “) and Ningbo Fubang Jingye Group Co.Ltd(600768) Holding Group Co., Ltd. (hereinafter referred to as “Fubang group”), Fubang Group signed the share transfer agreement with Bank Of Ningbo Co.Ltd(002142) , and Fubang group plans to transfer 39000000 Zhejiang Yatai Pharmaceutical Co.Ltd(002370) shares held by Bank Of Ningbo Co.Ltd(002142) at a price of 5.21 yuan / share, Accounting for 7.27% of the total share capital of Zhejiang Yatai Pharmaceutical Co.Ltd(002370) . The transfer price of the subject shares is determined as RMB 5.21 per share, and the total transfer price is RMB 203190000.00. After the completion of this share transfer, Fubon group and its persons acting in concert held 96675566 Zhejiang Yatai Pharmaceutical Co.Ltd(002370) shares, accounting for 18.02% of the total share capital of the company; Bank Of Ningbo Co.Ltd(002142) no longer holds Zhejiang Yatai Pharmaceutical Co.Ltd(002370) shares. For details, see the suggestive announcement on the transfer of shares and changes in equity by shareholders\’ agreement disclosed by the company on January 12, 2022. 7. The company has no other circumstances in violation of the provisions on fair information disclosure.
3、 There is no explanation that should be disclosed but not disclosed
The board of directors of the company confirms that the company does not have any matters that should be disclosed but not disclosed in accordance with relevant provisions such as the Listing Rules of Shenzhen Stock Exchange; The board of directors has not been informed that the company has undisclosed information that should be disclosed in accordance with the stock listing rules of Shenzhen Stock Exchange and other relevant provisions and has a great impact on the trading price of the company’s shares and their derivatives; There is no need to correct or supplement the information disclosed by the company in the early stage.
4、 Risk tips
1. Through self-examination, the company does not violate the fair disclosure of information.
2. The company solemnly reminds investors that the information disclosure media designated by the company are securities times and cninfo (www.cn. Info. Com. CN.), All information of the company shall be subject to the official announcement published in the above designated media.
The company will conscientiously perform the obligation of information disclosure and do a good job of information disclosure in a timely manner in strict accordance with the provisions and requirements of relevant laws and regulations. Please invest rationally and pay attention to investment risks.
It is hereby announced.
Zhejiang Yatai Pharmaceutical Co.Ltd(002370) board of directors
January 12, 2022
